CNS & Neurological Disorders - Drug Targets

Formerly Current Drug Targets - CNS & Neurological Disorders


Edoardo Spina
Department of Clinical and Experimental Medicine
University of Messina
Policlinico Universitario
Via Consolare Valeria

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 13 Issue: 1, February 2014

Message from Editor-in-Chief

Volume:13   Issue: 1
Pp: 1-1
Stephen D. Skaper
DOI: 10.2174/187152731301140210113429
Published on: 09 February, 2014

Conference Report: (13th International Congress on Amino Acids, Peptides and Proteins (ICAPP); Neurobiology Symposium, October 5-7, 2013; Galveston TX, USA.)

Volume:13   Issue: 1
Pp: 2-3
Hari Sharma, Dafin F Muresanu and Aruna Sharma
DOI: 10.2174/187152731301140210114550
Published on: 09 February, 2014

Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)

Volume:13   Issue: 1
Pp: 4-5
Susanna Amadio and Cinzia Volonte
DOI: 10.2174/18715273113126660148
Published on: 18 September, 2013

Editorial (Thematic Issues: Pharmacological Intervention for Down Syndrome Cognitive Deficits: Emerging Drug Targets)

Volume:13   Issue: 1
Pp: 6-7
Maria Luz Montesinos
DOI: 10.2174/18715273113126660187
Published on: 22 October, 2013

Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome

Volume:13   Issue: 1
Pp: 8-15
Marie-Claude Potier, Jerome Braudeau, Luce Dauphinot and Benoit Delatour
DOI: 10.2174/18715273113126660185
Published on: 22 October, 2013

The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration

Volume:13   Issue: 1
Pp: 16-25
Alberto C.S. Costa
DOI: 10.2174/18715273113126660183
Published on: 22 October, 2013

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

Volume:13   Issue: 1
Pp: 26-33
Walter Becker, Ulf Soppa and Francisco J. Tejedor
DOI: 10.2174/18715273113126660186
Published on: 22 October, 2013

The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits

Volume:13   Issue: 1
Pp: 34-40
Jose Antonio Troca-Marin, Juan Jose Casanas, Itziar Benito and Maria Luz Montesinos
DOI: 10.2174/18715273113126660184
Published on: 22 October, 2013

Editorial: Current Strategies in Targeting Brain Disorders

Volume:13   Issue: 1
Pp: 41-41
Perumal Yogeeswari
DOI: 10.2174/18715273113126660193
Published on: 22 October, 2013

Necroptosis: Who Knew There were so Many Interesting Ways to Die?

Volume:13   Issue: 1
Pp: 42-51
S.M. Fayaz, V.S. Suvanish Kumar and G.K. Rajanikant
DOI: 10.2174/18715273113126660189
Published on: 22 October, 2013

Recent Approaches for Studying the Role of Glia

Volume:13   Issue: 1
Pp: 52-62
Seyeon Park
DOI: 10.2174/18715273113126660191
Published on: 22 October, 2013

Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets

Volume:13   Issue: 1
Pp: 63-81
Matharasala Gangadhar, Ram Kumar Mishra, Dharmarajan Sriram and Perumal Yogeeswari
DOI: 10.2174/18715273113126660192
Published on: 22 October, 2013

Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications

Volume:13   Issue: 1
Pp: 82-95
Girish Chandran and Muralidhara
DOI: 10.2174/18715273113126660188
Published on: 22 October, 2013

Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs

Volume:13   Issue: 1
Pp: 96-103
Tanisha Singh, Abhishek Jauhari, Ankita Pandey, Parul Singh, Aditya B Pant, Devendra Parmar and Sanjay Yadav
DOI: 10.2174/18715273113126660190
Published on: 22 October, 2013

Blockade of MK-801-Induced Heat Shock Protein 72/73 in Rat Brain by Antipsychotic and Monoaminergic Agents Targeting D2, 5-HT1A, 5-HT2A and α1-Adrenergic Receptors

Volume:13   Issue: 1
Pp: 104-111
Tamara Romon, Anna M. Planas and Albert Adell
DOI: 10.2174/18715273113129990110
Published on: 27 August, 2013

Pathogenesis of Alzheimer Disease: Role of Oxidative Stress, Amyloid-β Peptides, Systemic Ammonia and Erythrocyte Energy Metabolism

Volume:13   Issue: 1
Pp: 112-119
Elena A. Kosenko, Iliya N. Solomadin, Lyudmila A. Tikhonova, V. Prakash Reddy, Gjumrakch Aliev and Yury G. Kaminsky
DOI: 10.2174/18715273113126660130
Published on: 16 September, 2013

Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

Volume:13   Issue: 1
Pp: 120-125
Subramanian Rajagopalan, Shankar J. Chinta and Julie K. Andersen
DOI: 10.2174/18715273113126660131
Published on: 16 September, 2013

Reconceptualizing Adult Neurogenesis: Role for Sphingosine-1-Phosphate and Fibroblast Growth Factor-1 in Co-Ordinating Astrocyte-Neuronal Precursor Interactions

Volume:13   Issue: 1
Pp: 126-136
George Anderson and Michael Maes
DOI: 10.2174/18715273113126660132
Published on: 16 September, 2013

TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease

Volume:13   Issue: 1
Pp: 137-149
George Anderson and Michael Maes
DOI: 10.2174/18715273113129990082
Published on: 09 July, 2013

Anxiety: A Systematic Review of Neurobiology, Traditional Pharmaceuticals and Novel Alternatives from Medicinal Plants

Volume:13   Issue: 1
Pp: 150-165
Erica Aparecida Gelfuso, Daiane Santos Rosa, Ana Lúcia Fachin, Márcia Renata Mortari, Alexandra Olimpio Siqueira Cunha and Rene Oliveira Beleboni
DOI: 10.2174/18715273113129990102
Published on: 27 August, 2013

Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation

Volume:13   Issue: 1
Pp: 166-172
Tingting Chen, Shajun Zhu, Siyuan Liu, Yapeng Lu and Li Zhu
DOI: 10.2174/18715273113129990076
Published on: 05 July, 2013

Searching for Disease-Modifying Drugs in AD: Can We Combine Neuropsychological Tools with Biological Markers?

Volume:13   Issue: 1
Pp: 173-186
Filippo Caraci, Sabrina Castellano, Salvatore Salomone, Filippo Drago, Paolo Bosco and Santo Di Nuovo
DOI: 10.2174/18715273113129990103
Published on: 27 August, 2013